// startup autopsy

ICAgen

Ion channel pioneer absorbed before it could prove its science.

marketfitAcqui-hire

Fatal mistake: ICAgen burned nearly two decades of capital on ion channel drug candidates without securing a major licensing partner to validate or fund its pipeline before cash ran out.

Founded	1992
Closed	2011
Country	USA
Sector	Biotech

50%

Key Events Timeline

1992-01-01

FOUNDING

ICAgen founded in North Carolina to develop ion channel-targeted therapeutics.

2000-06-01

PRODUCT LAUNCH

ICAgen advances lead ion channel compounds into preclinical and early clinical development.

2009-03-01

FUNDING

ICAgen receives its last disclosed funding round of $5M as pipeline progress slows.

2011-06-01

ACQUISITION ATTEMPT

Pfizer acquires ICAgen to absorb its ion channel research platform and scientific team.

2011-12-01

SHUTDOWN

ICAgen ceases independent operations following Pfizer acquisition, ending 19 years as a standalone biotech.

Full Analysis

Analyst plan

Documented cause

ICAgen developed ion channel drugs for pain and cardiovascular disease but failed to achieve clinical success. The company's pipeline stalled as its drug candidates did not meet clinical efficacy or safety endp...

oints, causing the company to struggle with funding. With clinical progress halted and venture capital sources drying up, ICAgen could not sustain independent operations. Pfizer acquired the company i

Verified lesson

“...”

Unlock full lesson →

€6.5M

Peak valuation

HypeCycle · MoatType · ResearchTags

ICAgen raised €5M before icagen burned nearly two decades of capital on ion channel drug candidates without securing a major licensing partner to validate or fund its pipeline before cash ran out. ended it. See the documented cause, verified lesson and all failure signals.

Unlock full analysis →Create free account

See all plans·Analyst plan — €149/mo